Table of Contents
- Roberto Mignone’s Career & Business Ventures
- Teva Pharmaceuticals: Stock Holdings & Insider Trading
- Bridger Management & Blue Ridge Capital’s Role
- Net Worth Discrepancies Explained
- 10 Key Facts About Roberto Mignone’s Net Worth
- Frequently Asked Questions
Roberto Mignone’s Career & Business Ventures
Roberto Mignone’s journey to wealth began in New York City, where he worked as a runner on the New York Stock Exchange in the late 1980s. Rising from this entry-level role, he leveraged his financial acumen to found Blue Ridge Capital LLC in 1996 and later Bridger Management LLC in 2000. These ventures laid the foundation for his multimillion-dollar net worth.
By 2017, Mignone had joined the board of directors at Teva Pharmaceutical Industries Limited, a position that would become central to his financial profile. His dual roles as a hedge fund manager and corporate board member illustrate the complexity of his wealth sources. Notably, his early career at the NYSE provided firsthand experience with market volatility, which he later applied to Bridger Management’s investment strategies.
Blue Ridge Capital, though less publicized, played a critical role in his early success. The firm focused on mid-cap growth stocks and distressed debt, strategies that later defined Bridger Management’s approach. Mignone’s ability to identify undervalued assets during the dot-com boom and the 2008 financial crisis showcased his adaptability in shifting markets.
Teva Pharmaceuticals: Stock Holdings & Insider Trading
Stock Transactions Since 2021
As of June 2026, Mignone owns 487,407 shares of TEVA stock, valued at fluctuating prices depending on market conditions. Over the past five years, he has executed multiple insider trades. Notably, he sold 1.1 million shares of TEVA stock between 2021 and 2025, generating $23.6 million in proceeds. His most recent transaction was a sale of 77,400 shares on December 16, 2025, as reported in SEC filings. These trades align with Teva’s broader strategy to streamline operations and focus on core businesses like generic drugs and over-the-counter products.
Impact on Net Worth
The volatility of Teva’s stock price contributes to the discrepancy in net worth estimates. For example, QuiverQuant calculates his net worth at $39.5 million as of June 2026, focusing on stock valuations. Meanwhile, Cine Net Worth cites a 2025 estimate of $1.5 billion, which may include unrealized gains from hedge fund assets. The divergence highlights the importance of timing and market conditions in wealth calculations. During periods of high Teva stock prices, his holdings could represent a larger portion of his net worth, while dips in value would reduce their contribution.
Insider trading laws require Mignone to file Form 4 with the SEC for each transaction, detailing the number of shares, price, and transaction type. These filings are publicly accessible and form the basis for platforms like QuiverQuant to track his activity. However, the absence of real-time data on private assets or Bridger Management’s performance means these estimates remain speculative.
Bridger Management & Blue Ridge Capital’s Role
Bridger Management’s $155.54M Fund
Mignone’s Bridger Management LLC, founded in 2000, is a key component of his financial empire. According to TipRanks, the fund’s reported net worth is $155.54 million as of 2026. This figure likely reflects the value of its portfolio, which includes equities, private equity, and alternative investments. Bridger Management’s strategy emphasizes long-term growth, with a focus on sectors like healthcare, technology, and renewable energy.
The fund’s performance is tied to Mignone’s personal wealth. For instance, a 10% annual return on the $155.54 million portfolio would generate $15.5 million in gains—equivalent to nearly half of his Teva stock sales in 2025. This interdependence underscores the need to analyze both his corporate and private investments when assessing net worth.
Blue Ridge Capital’s Legacy
Though less publicized, Blue Ridge Capital LLC (founded in 1996) played a foundational role in Mignone’s early wealth accumulation. As a partner, he developed strategies that would later define Bridger Management’s success. The firm’s focus on mid-cap growth stocks and distressed debt remains a hallmark of his investment philosophy. Blue Ridge’s early investments in companies like Vertex Pharmaceuticals and Zimmer Biomet contributed significantly to his net worth before Bridger Management’s launch.
Blue Ridge’s dissolution in the early 2000s marked a strategic shift toward larger-scale asset management. Mignone’s transition to Bridger Management allowed him to leverage institutional-grade resources while maintaining the agility of a smaller firm. This evolution reflects his ability to adapt to market demands while preserving core investment principles.
Net Worth Discrepancies Explained
Valuation Methodology
The gap between $39.5 million and $1.5 billion stems from differing valuation approaches. QuiverQuant bases its 2026 estimate on liquid assets like Teva stock, while Cine Net Worth’s 2025 figure likely incorporates Bridger Management’s $155.54 million fund and private assets. InsiderTrades.com notes that corporate director roles often include deferred compensation and stock options, further complicating calculations.
Third-party platforms like Net Worth Genius and Cine Net Worth often rely on outdated or aggregated data. For instance, the $1.5 billion estimate from July 2025 may include speculative valuations of Mignone’s real estate holdings or unrealized gains from Bridger Management. In contrast, QuiverQuant uses real-time SEC filings to track stock sales, resulting in a lower but more conservative figure.
Why the Gap?
Estimates vary due to the treatment of illiquid assets. Bridger Management’s $155.54 million fund includes private equity stakes and venture capital investments that are difficult to value accurately. These assets may not be reflected in stock-based estimates, leading to the $1.5 billion figure. Conversely, QuiverQuant’s focus on Teva stock and recent trades excludes these components, resulting in a lower estimate.
Another factor is the timing of trades. For example, if Mignone sold a large block of Teva stock in 2025 at a high price, this would temporarily inflate net worth estimates. However, subsequent market declines could erase those gains, creating a misleading picture. This volatility underscores the importance of using multi-year data when analyzing net worth.
10 Key Facts About Roberto Mignone’s Net Worth
1. Net Worth Range
Estimates range from $39.5 million (QuiverQuant, June 2026) to $1.5 billion (Cine Net Worth, July 2025), depending on valuation methods.
2. Teva Stock Holdings
Owns 487,407 shares of TEVA stock as of June 2026; recent insider trades include $23.6 million in sales since 2021.
3. Bridger Management’s Value
TipRanks reports Bridger Management’s net worth at $155.54 million as of 2026.
4. Blue Ridge Capital’s Legacy
Founded in 1996; laid the groundwork for Mignone’s investment strategies.
5. Insider Trading Activity
Sold 1.1 million TEVA shares between 2021 and 2025, with the most recent sale of 77,400 shares on December 16, 2025.
6. Career Origins
Began as a NYSE runner in the 1980s, rising through the ranks to become a successful trader.
7. Teva Board Role
Served on Teva’s board since 2017; owns shares valued at fluctuating prices.
8. Real Estate Holdings
Part of the Mignone Group, a global real estate and investment firm (mentioned in Cine Net Worth, 2025).
9. Philanthropy
Details on charitable efforts are sparse, but his wealth suggests potential for large-scale donations.
10. Future Projections
Market trends suggest his net worth could grow if Bridger Management’s investments continue to perform well.
Data Tables
Table 1: Net Worth Estimates by Source
| Source | Date | Estimated Net Worth | Methodology |
|---|---|---|---|
| QuiverQuant | June 2026 | $39.5 million | Stock holdings + recent trades |
| Cine Net Worth | July 2025 | $1.5 billion | Includes Bridger Management + private assets |
| TipRanks | 2026 | $155.54 million | Bridger Management fund value |
Table 2: TEVA Stock Transactions
| Date | Shares Sold | Proceeds |
|---|---|---|
| 2021–2025 | 1.1 million | $23.6 million |
| Dec 16, 2025 | 77,400 | $1.2 million (approx.) |
Frequently Asked Questions
1. How did Roberto Mignone start his career?
Mignone began as a runner on the New York Stock Exchange in the 1980s. His early exposure to high-stakes trading helped him rise through the ranks and eventually launch his own investment firms. This experience provided him with a deep understanding of market mechanics, which he later applied to Bridger Management’s strategies.
2. What is Bridger Management’s role in his net worth?
Bridger Management, founded in 2000, is a $155.54 million hedge fund as of 2026. Its performance and asset allocation significantly influence Mignone’s overall wealth. The fund’s diversified portfolio, including equities and private equity, ensures steady growth even during market downturns.
3. Why does his net worth vary so much?
Estimates range from $39.5 million to $1.5 billion due to differing methodologies—stock valuations vs. hedge fund assets, realized vs. unrealized gains, and private equity holdings. The treatment of illiquid assets like Bridger Management’s private equity stakes further complicates calculations.
4. How much has he sold in TEVA stock?
Since 2021, Mignone has sold 1.1 million TEVA shares for $23.6 million, with a recent sale of 77,400 shares on December 16, 2025. These transactions reflect his strategy to balance risk and reward in his Teva holdings.
5. Is he involved in philanthropy?
Public records offer limited details on Mignone’s charitable efforts, though his net worth suggests he could fund large-scale initiatives. His potential contributions might align with causes like healthcare innovation or financial literacy programs, given his background.
6. What’s next for his wealth?
Future net worth projections depend on Bridger Management’s investment performance and Teva Pharmaceuticals’ stock price movements. If the fund continues to outperform market benchmarks, his net worth could rise significantly by 2027.
Conclusion
Roberto Mignone’s net worth remains a topic of debate due to the complexity of his financial holdings. While some sources highlight his $39.5 million in Teva stock sales (QuiverQuant, 2026), others cite a $1.5 billion fortune (Cine Net Worth, 2025), which likely includes Bridger Management’s $155.54 million fund and private assets. Understanding these discrepancies requires analyzing valuation methods, insider trading activity, and the role of his hedge fund in his overall wealth.
For readers seeking a comprehensive view, it’s crucial to consider both liquid assets like TEVA stock and illiquid investments such as Bridger Management’s portfolio. As markets evolve, so too will Mignone’s net worth, making ongoing analysis essential for accurate assessments. Whether his wealth grows or contracts in the coming years, his financial strategies will remain a case study in the interplay between corporate governance, hedge fund management, and stock market volatility.
